Status:
COMPLETED
The Use of Inflammatory Markers to Guide Therapy in Children With Severe Asthma
Lead Sponsor:
Royal Brompton & Harefield NHS Foundation Trust
Collaborating Sponsors:
National Heart and Lung Institute
Imperial College London
Conditions:
Asthma
Eligibility:
All Genders
8-18 years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether using non-invasive measurements of airway inflammation can improve clinical decision making in children with severe asthma compared to conventional ma...
Detailed Description
Children with severe asthma pose a management dilemma; it is difficult to reduce their treatment while they are symptomatic, but the plateau of the dose response curve for inhaled corticosteroids (ICS...
Eligibility Criteria
Inclusion
- Children \>8 years with severe asthma defined as:
- Taking at least 500mcg fluticasone propionate (or equivalent) per day, plus a long acting beta agonist plus a leukotriene antagonist or previous trial
Exclusion
- Children taking steroid sparing agent (cyclosporin, azathioprine, methotrexate) Children with other major respiratory diagnoses such as bronchiectasis
- \-
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT00262340
Start Date
December 1 2005
End Date
February 1 2008
Last Update
October 29 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Brompton Hospital
London, United Kingdom, SW3 6NP